A Phase 2 CT to Evaluate the Safety and Efficacy of Topical Administration of Bacteriophage Therapy TP-102 in Patients With DFI
Latest Information Update: 02 Jun 2025
At a glance
- Drugs TP-102 (Primary)
- Indications Bacterial infections; Diabetic foot ulcer
- Focus Adverse reactions; Therapeutic Use
- Acronyms REVERSE2
- Sponsors Technophage
Most Recent Events
- 25 May 2025 Planned End Date changed from 31 Dec 2024 to 31 Dec 2025.
- 25 May 2025 Planned primary completion date changed from 30 Dec 2024 to 30 Nov 2025.
- 05 Aug 2024 Planned End Date changed from 31 Jul 2024 to 31 Dec 2024.